Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada.
Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario, M5G 0A4, Canada.
Cancer Med. 2018 May;7(5):1750-1755. doi: 10.1002/cam4.1433. Epub 2018 Mar 23.
Objectives were to describe any bothersome symptom and severely bothersome symptoms in inpatient children with cancer and hematopoietic stem cell transplant (HSCT) recipients. We included children 8-18 years of age with cancer or HSCT recipients who were receiving active treatment for cancer, admitted to hospital, and expected to be in hospital 3 days later. We administered the self-report Symptom Screening in Pediatrics Tool (SSPedi). We described those who identified any degree of symptom bother (at least "a little") and those who rated the degree of bother as severe ("a lot" or "extremely"). Factors associated with severe symptoms and total SSPedi scores were examined using multiple logistic and linear regression. Among the 302 patients, 298 (98.7%) reported having any bothersome symptom and 181 (59.9%) had at least one severely bothersome symptom. In multiple regression, older children were significantly more likely to have at least one severely bothersome symptom (15-18 and 11-14 years vs. 8-10 years; P = 0.008) and to have higher total SSPedi scores (P = 0.0003). Those with relapsed disease were more likely to have at least one severely bothersome symptom (odds ratio 2.1, 95% confidence interval 1.1-4.3; P = 0.037) and HSCT recipients were more likely to have higher symptom scores (β = 3.48, standard error = 1.6; P = 0.030). Almost all children receiving cancer therapies experience bothersome symptoms and 60% have at least one severely bothersome symptom. Older children experienced more severely bothersome symptoms and higher symptom scores. Future studies should follow children longitudinally to better understand the symptom trajectory and should institute interventions to manage symptoms.
目的在于描述患有癌症和造血干细胞移植(HSCT)接受者的住院儿童中任何令人烦恼的症状和严重令人烦恼的症状。我们纳入了 8-18 岁患有癌症或 HSCT 接受者的儿童,他们正在接受癌症的积极治疗,住院,并预计在 3 天后住院。我们使用自我报告的儿科症状筛查工具(SSPedi)进行了评估。我们描述了那些报告有任何程度的症状困扰(至少“有点”)和那些将困扰程度评为严重(“很多”或“非常”)的人。使用多元逻辑回归和线性回归分析了与严重症状和 SSPedi 总分相关的因素。在 302 名患者中,有 298 名(98.7%)报告有任何令人烦恼的症状,有 181 名(59.9%)有至少一种严重令人烦恼的症状。在多元回归中,年龄较大的儿童更有可能有至少一种严重的令人烦恼的症状(15-18 岁和 11-14 岁与 8-10 岁相比;P=0.008),并且 SSPedi 总分更高(P=0.0003)。疾病复发的患者更有可能有至少一种严重的令人烦恼的症状(优势比 2.1,95%置信区间 1.1-4.3;P=0.037),并且 HSCT 接受者的症状评分更高(β=3.48,标准误差=1.6;P=0.030)。几乎所有接受癌症治疗的儿童都会经历令人烦恼的症状,有 60%的儿童至少有一种严重令人烦恼的症状。年龄较大的儿童经历了更严重的令人烦恼的症状和更高的症状评分。未来的研究应该对儿童进行纵向随访,以更好地了解症状轨迹,并应制定干预措施来管理症状。